Steroids and process for preparing the same

ABSTRACT

The present invention relates to 2-chloro-6β-fluoro-pregna-1,4-diene-3,20-diones having good anti-inflammatory activity, to processes for their preparation and pharmaceutical compositions thereof.

This is a division of application Ser. No. 024,460, filed Mar. 27, 1979, now U.S. Pat. No. 4,275,061; which is a continuation of Ser. No. 839,881, filed Oct. 6, 1977, now abandoned; which is a continuation of Ser. No. 596,266, filed July 16, 1975, now abandoned.

The present invention relates to a new class of steriods having good anti-inflammatory activity, to processes of making them and to pharmaceutical compositions containing them.

Many steroids having anti-inflammatory activity upon topical and/or systemic administration are known and some of them have quite satisfactory anti-inflammatory activity.

Unfortunately they all tend to give undesired side effects. For instance they may disturb the mineral balance in the subject to which they are administered, for example they may reduce the potassium and/or sodium balance and they may affect adversely the adrenals function.

Accordingly their application has to be conducted with caution. It has been our object to produce novel steroids that have very good anti-inflammatory activity, preferably higher than that of most or all known steroids, and which have very low or no side effects, preferably when measured in absolute terms but in particular when measured as the therapeutic ratio, i.e. the ratio of the active dose that is required to achieve the desired anti-inflammatory activity to the minimum dose that incurs undesired side effects.

We have now found that 2-chloro-6β-fluoro-pregna-1,4-diene-3,20-diones have high anti-inflammatory activity and at same time avoid conpletely or at least minimise the undesirable side effects of known steroid compound.

The preferred novel compounds of the invention have the general formula ##STR1## wherein X represents Br, Cl, or OQ;

Y represents Br, Cl, F or H;

R₁ represents OQ;

R₂ represents OQ;

R₃ represents H, αOQ, αCH₃ or βCH₃ ;

and the radicals Q, which may be the same or different, are selected from H and acyl radicals, or the groups OQ in the 16 and 17 positions or in the 17 and 21 positions may together form a cyclic ketal, cyclic acetal or cyclic alkyl orthoester, and pharmaceutically acceptable salts or esters with those compounds wherein at least one radical Q is a polycarboxylic or an inorganic acid radical.

The salts are preferably water soluble and are preferably with an alkali metal, for example sodium or potassium. The esters are preferably with an aliphatic, aryl, arylaliphatic or cycloaliphatic group.

The OQ group of R₁ can be also an alkyl orthoester.

Typical values of aliphatic radicals suitable as the esterifying radical in a dicarboxylic acyl group are alkyl, preferably containing up to 7 carbon atoms and alkenyl. Particularly preferred are alkyl containing up to 4 carbon atoms, especially methyl, ethyl and propyl. Typical cycloaliphatic are cycloalkyl radicals containing 5 to 8 carbon atoms, for example cyclopentyl and cyclohexyl.

Typical arylaliphatic radicals are phenyl alkyl radicals, for example where alkyl is as described above, for instance benzyl.

Typical aryl radicals are those containing a phenyl ring, for example unsubstituted phenyl.

When Q is acyl, OQ thus being an ester radical, Q may be the radical of an inorganic acid, for example sulphuric acid or phosphoric acid, or an organic acid, for example a sulphonic acid or a carboxylic acid, including aliphatic, alicyclic, aromatic, arylaliphatic and heterocyclic carboxylic acids, including carboxylic acids such as thiocarboxylic acids and amino carboxylic acids. Preferred carboxylic acids are formic acid, acetic acid, chloroacetic acid, trifluoroacetic acid, propionic acid, butyric acid, valeric acid, trimethylacetic acid, diethylacetic acid, caproic acid, erotonic acid, enanthic acid, caprylic acid, capric acid, palmitic acid, undecanic acid, undecylenic acid, oxalic acid, succinic acid, glutaric acid, pimelic acid, tartaric acid, maleic acid, lactic acid, carbamic acid, glycine, alkoxy carboxylic acids, hexahydrobenzoic acid, cyclopentylpropionic acids, cyclohexylacetic acid, cyclohexylbutyric acids, benzoic acid, phthalic acid, phenylacetic acid, phenylpropionic acids, furane-2-carboxylic acid, nicotinic acid and isoicotinic acid.

Preferred sulphonic acids are methanesulphonic acid and toluenesulphonic acid.

Particularly preferred acyl radicals are those derived from acetic acid, trimethylacetic acid, propionic acid, β-phenyl-propionic acid, α-phenylpropionic acid, valeric acid and dicarboxylic acids, for example succinic acid.

It is often preferred that in R₁ Q shall be an acyl group as described above, particularly the preferred carboxylic acyl groups as described above, since 21-esters have particularly good biological activity. It is often preferred that when X represents OQ, Q shall be hydrogen. Any convenient cyclic ketals or cyclic acetals may be formed at the 16,17 or 17,21 positions but are preferably acetonides or 17,21 methylene dioxy derivatives.

Suitable cyclic orthoesters that may be formed at these positions include the 17,21 methylorthoacetate, the 17,21 ethylorthopropionate, the 17,21 methylorthobenzoate and the 17,21 methylorthovalerate. One preferred class of compounds of the invention are those wherein R₃ represents H or αOQ, especially OH.

Another preferred class of compounds of the invention are those wherein R₃ represent α or β methyl, most preferably α methyl.

It is often preferred that Y should be halogen, X can also be halogen and thus some preferred compounds of the invention have both X and Y representing halogen, usually both representing chlorine or both representing bromine.

However, it is generally preferred that Y shall represent halogen and X shall represent OQ, preferably OH.

Preferred values of Y are bromine and, especially, fluorine. Thus particularly preferred compounds of the invention are 9α-halo (especially fluoro) 11β-hydroxy compounds.

It is of course already well known to make pregna-1,4-diene-3,20-dione compounds. It is also known to produce a few 2-chloro steriods. Further, it is well known to make 6α-fluoro steriods. There have been some references to the production of 6β-fluoro steriods in the literature but it seems to have been considered generally in the art that 6β-fluoro steriods are interior pharmaceutically to 6α-fluoro steriods. The combination of 2-chloro with 6β-fluoro in pregna-1,4-diene-3,20-diones appears to be new and gives good anti-inflammatory activity with low or negligible side effects as discussed above.

New compounds of the present invention to be particularly emphasized are:

9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (6a)

9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6b)

9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6c)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8a)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8b)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8c)

2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8d)

2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8e)

2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8f)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8g)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8h)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8i)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8k)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione (8m)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8n)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8o)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-acetate (8p)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8q)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8r)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-21-acetate (8s)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8t)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8u)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8v)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8w)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8z)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8aa)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8ab)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8ac)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-valerate (8ad)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-acetate (8ae)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8af)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8ag)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-17-acetate (8ah)

2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8ai)

2,9α,11β-trichloro-6α-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8aj)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-acetate (8ak)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-acetonide (8al)

2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-acetonide (8am)

2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10a)

2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione (10b)

2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-16,17-acetonide-21-acetate (11a)

2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-16,17-acetonide (11b)

2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-16,21-diacetate (12a)

The novel compounds of the invention have good anti-inflammatory activity. This activity can be exhibited upon conventional methods of administration, for example topically and systemically.

Some compounds give best results topically while others give best results systemically, for instance when taken orally as is preferred. Because of the very high activity possessed by preferred compounds of the invention lower dosages can be used than are useful with known anti-inflammatory steriods; even at conventional dosages preferred compounds of the invention have much less, and generally no, side effects compared with known anti-inflammatory steriods.

The compounds of the invention are useful for treatment of a wide variety of inflammatory conditions, for example in the treatment of inflammatory conditions of the skin, eyes and ears of humans and of valuable domestic animals, as well as contact dermatitis and other allergic reactions and also possess valuable antirheumatoid arthritic properties.

Therapeutic compositions of the invention comprise a compound of the invention together with a pharmaceutically acceptable liquid or solid carrier. Any therapeutically acceptable and effective concentration of the compound in the composition may be used. Any suitable composition may be prepared, according to the chosen manner of administration. Suitable compositions include pills, tablets, capsules, solutions syrups or elixirs for oral use, liquid forms of the types used to make injectable compositions of the natural and synthetic cortical steriods hormones, and topical compositions, for example in the form of ointments, creams and lotions.

The compositions may also include coacting antibiotics, germicides or other materials forming advantageous combination therewith.

The local anti-inflammatory activity has been evaluated in rats by the cotton-pellet induced granuloma test, applying the compound directly to the pellet.

All the new compounds of the present invention show a remarkable anti-inflammatory activity without undesirable side effects on the thymus and on the body weight increase even at very high concentrations (40 micrograms/pellet).

The most active compounds inhibit the cotton-pellet induced granuloma at doses ranging from 0.01 to 1 microgram/pellet whereas hydrocortisone acetate shows the same activity at about 100-200 micrograms/pellet. The systemic anti-inflammatory activity has been evaluated in rats by cotton-pellet induced granuloma test, giving the compounds orally for 8 days. The most active compounds show activity at doses ranging from 0.5 to 5 mg/kg b.w., while Hydrocortisone acetate and Methylprednisolone are active at doses ranging from 10 to 50 mg/kg b.w. Most of the compounds of the present invention have, on this test, no inhibiting action on adrenals weight and a thymolitic or body weight reducing activity lower than that displayed by the most active already known steroids.

A preferred reaction scheme for making compounds of formula A is shown below. Preferred methods of carrying out each of the process steps shown in the scheme are described subsequently.

Of course alterations to the described reaction conditions can be used: e.g. oxidising agents other than potassium permanganate and solvents other than pyridine can be used. ##STR2##

The starting substance used for the preparation of the compounds of the present invention is 6β-fluoro-3,5α, 11α,17α,21-pentahydroxy-pregn-2-ene-20-one-3,5,17,21-tetracetate-11-mesylate or 6β-fluoro-3,5α,11α,17α,21-pentahydroxy-16-methyl-pregn-2-ene-20-one-3,5,17,21-tetracetate-11-mesylate, which are described in British Patent Application No. 55799/74. In the specification the term "16 methyl" is to be understood as meaning both 16α-methyl and 16β-methyl.

Chlorination of the compound 1 with 2,5 equivalents of chlorine in dioxane produces a 80:20 mixture of chloro-compounds 2 and 3. No further chlorination is observed by repeating this experiment with a five-fold excess of chlorine.

In contrast chlorination of the mixture to give 4 is completed with only 1,2 equivalents of chlorine in acetic acid.

The combination of certain metal halides, particularly lithium chloride and bromide in hot dimethylformamide is particularly effective to obtain the corresponding triene 5 from 4.

Other amide solvents, such as dimethylacetamide and N-formylpiperidine can be used in place of dimethylformamide. A modification involves the use of an excess of lithium carbonate in dimethylformamide.

The reaction of the compound 5 with hypobromous acid produces the corresponding 9α-bromo compound 6. When this 9α-bromo compound is reacted with potassium carbonate the 9β,11β-oxido compound 7 is obtained. Reaction of the latter compound with hydrofluoric acid affords 8 where X=OH and Y=F, which upon hydrolysis is converted into the corresponding free alcohol.

Reaction of 7 with hydrochloric acid affords 8 where X=OH and Y=Cl. The triene 5 is reacted with N-chlorosuccinimide in presence of lithium chloride to obtain 8 where X=Y=Cl, which by hydrolysis is converted into the corresponding free alcohol.

The fluorine atom at the 6β-position of the compound 8 is considered to be in the stable configuration on the basis of the following observation. Attempts to isomerize it with dry hydrochloric acid in chloroform at 0° C. for 2 hrs. do not alter the optical rotatory dispersion curve of the crude product.

Recrystallization affords pure product identical in all aspects to the starting sample.

When the compound Sa (X OH, Y=F, R₃ =H, R₁ =R₂ =OCOCH₃) is reacted with potassium acetate in hot dimethylformamide the 2-chloro-6β,9α-difluoro-11β,21-dihydroxy-pregna-1,4,16-triene-21-acetate (9α X=OH, Y=F R₁ =OCOCH₃) is obtained and this is then oxidated with potassium permanganate to produce the corresponding 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10α X=OH, Y=F R₁ =OCOCH₃) which upon hydrolysis is converted into the corresponding free alcohol.

Esterification of the hydroxyl function at the 21-position is conveniently effected with a lower fatty acid anhydride, such as acetic anhydride, or preferably with a lower aliphatic acid chloride such as acetic acid chloride in presence of pyridine, which simultaneously serves as solvent.

The 17α-esters are prepared by treatment of the corresponding 17α,21 diols with a lower alkyl orthoesters in presence of an acid catalyst followed by acid hydrolysis of the resulting 17α,21-orthoester (a mixture of two epimeric orthoesters).

The esterification of the hydroxyl function at the 11-position is effected with a lower fatty acid anhydride in presence of perchloric acid or p-toluensulfonic acid.

The esterification of the hydroxyl function at the 21-position can also be achieved by trans-esterification of the corresponding 17α-esters.

Treatment of the corresponding 17α,21-diols with 2,2-dimethoxy-propane in presence of p-toluensulfonic acid produces the 17,21-acetonides.

Treatment of the compounds 10 with acetone and perchloric acid produces the 16,17-acetonides.

The esterification of the hydroxyl function at the 16-position of the compounds 10 is effected with a lower fatty acid anhydride in presence of pyridine which simultaneously serves as solvent.

EXAMPLE I

A solution of 15.75 g. of 6β-fluoro-3,5α,11α,17α,21-pentahydroxy-pregn-2-ene-20-one-3,5,17,21-tetracetate-11-mesylate (1a, R₃ =H) in 180 ml. of dioxane containing 0.54 g. of chlorine, was stirred at 5°-10° C. for 1 hr. and then poured into 1000 ml. of water and 45 g. of sodium chloride. The product was collected by filtration, washed neutral with water and dried (16 g.).

NMR of this material indicated a ˜80:20 mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2a, R₃ =H) and 2,2,-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-pregnan-3,20-dione-5,17,21,triacetate-11-mesylate (3a, R₃ =H).

The filtered solid was utilized in the next reaction without further purification.

EXAMPLE II

Using the general procedure of Example I the 6β-fluoro-3,5α,11α,17α,21-pentahydroxy-16α-methyl-pregn-2-ene-20-one-3,5,17,21-tetracetate-11-mesylate (1b, R₃ =αCH₃) was converted into the mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16.alpha.-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2b, R₃ =αCH₃) and 2,2-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16α-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (3b, R₃ =αCH₃). The mixture was utilized in the next reaction without further purification.

EXAMPLE III

Using the general procedure of Example I the 6β-fluoro-3,5α,11α,17α,21-pentahydroxy-16β-methyl-pregn-2-ene-20-one-3,5,17,21-tetracetate-11-mesylate (1c, R₃ =βCH₃) was converted into the mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16.beta.-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2c, R₃ =βCH₃) and 2,2-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16β-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (3c, R₃ =βCH₃).

The mixture was utilized in the next reaction without further purification.

EXAMPLE IV

16 g. of the mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2a, R₃ =H) and 2,2-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (3a, R₃ =H), obtained in Example I, were dissolved in 500 ml. of anhydrous acetic acid at 90° C. A solution of sodium acetate (38.5 g. dried at 100° C.) in acetic acid (500 ml.) at 90° C. was added, followed immediately by 30 ml. of 1 M chlorine solution in acetic acid, added in one portion. The solution was stirred at 90° C. for 20 min., cooled at 20° C., stirred for 0.5 hr., poured into a mixture of 700 ml. of ice and water.

The resulting pricipitate was collected by filtration and dissolved in chloroform. The solution was washed with water, 5% NaHCO₃ and water, dried and concentrated.

The residue was crystallized from ethanol to give 7 g. of 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-pregn-4-ene-3,20-dione-17,21-diacetate-11-mesylate (4a, R₃ =H) characterized by:

M.P. 173°-5° C. (decomposition).

[α]_(D) ²⁰ -12° (C 1.0 in chloroform).

λmax (methanol) 243 mμ (ε11200).

IR(KBr) 1745, 1730, 1710, 1625, 1240 cm⁻¹.

NMR (CDCl₃ -TMS) Hz at 60 mHz 364,360 (d, 1, C₄ -H) 328,278 (doublet of triplets, 1, C₆ -H) 320-290 (m, 1, C₁₁ -H) 302,286,280,264 (doublet of doublets, 2, --COCH₂ O--) 190 (S, 3, --OSO₂ CH₃) 130 (S, 1, OAc) 128 (S, 1, OAc) 106,102 (d, 3, C₁₀ -CH₃ split by 6βF) 52 (S, 1, C₁₃ -CH₃).

Analysis: Calcd. for C₂₆ H₃₃ Cl₂ FO₉ S (percent) C 51,07; H 5,44; Cl 11,59; F 3,11; S 5.24. Found (percent) C 50,89; H 5,44; Cl 11,67; F 3,09; S 5,27.

EXAMPLE V

Using the general procedure of Example IV the mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16.alpha.-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2b, R₃ =αCH₃) and 2,2-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16α-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (3b, R₃ =αCH₃), obtained in Example II, was converted into 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-16α-methyl-pregn-4-ene-3,20-dione-17,21-diacetate-11-mesylate (4b, R₃ =αCH₃).

IR(KBr) 1750, 1730, 1708, 1630, 1235 cm⁻¹.

Analysis Calcd. for C₂₇ H₃₅ Cl₂ FO₉ S (percent) C 51,84; H 5,64; Cl 11,34; F 3,04; S 5,13. Found (percent) C 52,04; H 5,70; Cl 11,32; F 3,07; S 5,12

EXAMPLE VI

Using the general procedure of Example IV the mixture of 2-chloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16.beta.-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (2c, R₃ =βCH₃) and 2,2-dichloro-6β-fluoro-5α,11α,17α,21-tetrahydroxy-16β-methyl-pregnan-3,20-dione-5,17,21-triacetate-11-mesylate (3, R₃ =βCH₃), obtained in Example III, was converted into 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-16β-methyl-pregn-4-ene-3,20-dione-17,21-diacetate-11-mesylate (4c, R₃ =βCH₃).

IR(KBr) 1745, 1730, 1710, 1630, 1235 cm⁻¹.

Analysis: Calcd. for C₂₇ H₃₅ Cl₂ FO₉ S (percent) C 51,84; H 5,64; Cl 11,34; F 3,04; S 5,13. Found (percent) C 51,90; H 5,62; Cl 11,29; F 3,04; S 5,18.

EXAMPLE VII

14.8 g. of 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-pregn-4-ene-3,20-dione-17,21-diacetate-11-mesylate (4a, R₃ =H) were added, in one portion, to a mixture of 120 ml. of dimethylformamide, 30 g. of lithium carbonate and 15 g. of lithium bromide under stirring at 100° C. The reaction mixture was then refluxed at 130° C. under nitrogen for 0.5 hr., cooled and poured into cold water. The precipitate was filtered off, washed with water, dried and absorbed on FLORISIL (Registered Trade Mark) (ratio 1:100) from 8:2 chloroform-benzene.

Elution with chloroform gave fractions which were recrystallized from benzene to give 4 g. of 2-chloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5a, R₃ =H) characterized by:

M.P. 264°-6° C. (decomposition).

[α]_(D) ²⁰ -73° (C 1.0 in chloroform).

IR(KBr) 1740, 1680, 1650, 1610, 1235 cm⁻¹.

NMR (CDCl₃ -TMS) Hz at 60 mHz 435 (S, 1, C₁ -H) 374.370 (d, 1, C₄ -H) 344-334 (m, 1, C₁₁ -H) 330, 280 (doublet of triplets, 1, C₆ -H) 300, 284, 278, 262 (doublet of doublets, 2, --COCH₂ O--) 128 (S, 1, OAc) 122 (S, 1, OAc), 94,92 (d, 3, C₁₀ -CH₃ split by 6βF) 45 (S, 1, C₁₃ -CH₃)

Analysis: Calcd. for C₂₅ H₂₈ ClFO₆ (percent) C 62,70; H 5,89; Cl 7,40; F 3,97. Found (percent) C 62,75; H 5,92; Cl 7,35; F 3,95.

EXAMPLE VIII

Using the general procedure of Example VII the 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-16α-methyl-pregn-4-ene-3,20-dione-17,21-diacetate (4b, R₃ =αCH₃) was converted into 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5b, R₃ =αCH₃) characterized by:

IR(KBr) 1740, 1680, 1645, 1235 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₀ ClFO₆ (percent) C 63,35; H 6,13; Cl 7,18; F 3,85. Found (percent) C 63,45; H 6,15; Cl 7,21; F 3,86.

EXAMPLE IX

Using the general procedure of Example VII the 2,2-dichloro-6β-fluoro-11α,17α,21-trihydroxy-16β-methyl-pregn-4-ene-3,20-dione-17,21-diacetate (4c, R₃ =βCH₃) was converted into 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5c, R₃ =βCH₃) characterized by:

IR(KBr) 1745, 1675, 1650, 1230 cm⁻¹.

Analysis Calcd. for C₂₆ H₃₀ ClFO₆ (percent) C 63,35; H 6,13; Cl 7,19; F 3,85. Found (percent) C 63,25; H 6,12; Cl 7,24; F 3,89.

EXAMPLE X

28 g. of 1,3-dibromo-5,5-dimethyl-hydantoin were added in the dark at 15° C. under stirring over a period of 0.5 hr. to a suspension of 3.63 g. of 2-chloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5a, R₃ =H) in 90 ml. of tetrahydrofurane and 0.45 g. of 70% perchloric acid in 4.5 ml. of water.

During the addition the suspension began to thin and after a total reaction time of 45 min. all the starting material was dissolved. After an additional 2 hr., 10% sodium sulfite aqueous solution was added under stirring until KJ-starch paper was no longer blued. The solution was slowly poured into 250 ml. cold water, the solid was filtered and utilized moist in the next reaction.

The 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-diene-17,21-diacetate (6a, R₃ =H) was filtered and utilized moist in the next reaction. Analytically pure 6a was obtained by crystallization from acetone-hexane.

M.P. 212°-4° C. (decomposition).

[α]_(D) ²⁰ -11° (C 1.0 in chloroform).

IR(KBr) 3420 (broad), 3325, 1755, 1740, 1675, 1645, 1610, 1235 cm⁻¹.

Analysis Calcd. for C₂₅ H₂₉ BrClFO₇ (percent) C 52,14; H 5,08; Br 13,88; Cl 6,16; F 3,30. Found (percent) C 52,37; H 5,08; Br 13,81; F 3.25.

EXAMPLE XI

Using the general procedure of Example X the 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5b, R₃ =αCH₃) was converted into 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6b, R₃ =αCH₃) characterized by:

IR (KBr) 3430 (broad), 1750, 1740, 1680, 1640, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ BrClFO₇ (percent) C 52,94; H 5,30; Br 13,55; Cl 6,01; F 3,22. Found (percent) C 52,92; H 5,35; Br 13,51; Cl 6,10; F 3,25.

However the product 6b was filtered and utilized moist in the next reaction.

EXAMPLE XII

Using the general procedure of Example X the 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5c, R₃ =βCH₃) was converted into 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16β-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6c, R₃ =βCH₃) characterized by:

IR(KBr) 3425 (broad), 1755, 1740, 1675, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ BrClFO₇ (percent) C 52.94; H 5,30; Br 13,55; Cl 6,01; F 3,22. Found (percent) C 53,07; H 5,33; Br 13,30; Cl 6,05; F 3,20.

However the product 6c was filtered and utilized moist in the next reaction.

EXAMPLE XIII

12 ml. of a 14% potassium carbonate aqueous solution were added over a period of 20 min. at 20° C. under stirring to the solution of the moist product (6a, R₃ =H) 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxyl-pregna-1,4-diene-3,20-dione-17,21-diacetate [obtained in Example X from 2.8 g. of the product 5a (R₃ =H)] in 75 ml. of acetone.

The solution was stirred for 3.5 hr. Ice water was added under stirring, upon which crystallization occurs rapidly. The product 2-chloro-6β-fluoro-17α,21-dihydroxy-9β,11β-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7a, R₃ =H) was filtered, washed with water, dried and characterized by M.P. 255°-6° C. (decomposition).

[α]_(D) ²⁰ -78° (C 1.0 in chloroform).

IR(KBr) 1760, 1745, 1735, 1670, 1645, 1605, 1235 cm⁻¹.

Analysis: Calcd. for C₂₅ H₂₈ ClFO₇ (percent) C 60,67; H 5,70; Cl 7,16; F 3,84. Found (percent) C 60,35; H 5,72; Cl 7,23; F 3,80.

EXAMPLE XIV

Using the general procedure of Example XIII the 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6b, R₃ =αCH₃) was converted into 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-9β,11β-oxide-pregna-1,4-diene-3,20-dione-17,21-diacetate (7b, R₃ =αCH₃) characterized by:

IR(KBr) 1750, 1740, 1670, 1640, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₀ ClFO₇ (percent) C 61,36; H 5,94; Cl 6,97; F 3,73. Found (percent) C 61,12; H 5,87; Cl 7,02; F 3,75.

EXAMPLE XV

Using the general procedure of Example XIII the 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-16β-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (6c, R₃ =βCH₃) was converted into 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-9β,11.beta.-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7c, R₃ =βCH₃) characterized by:

IR(KBr) 1755, 1740, 1675, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₀ ClFO₇ (percent) C 61,36; H 5,94; Cl 6,97;F 3,73. Found (percent) C 61,46; H 6,01; Cl 6,92; F 3,80.

EXAMPLE XVI

40 ml. of a 70% hydrofluoric acid aqueous solution were cooled to -10° C. in a polyethylene flask equipped with electromagnetic stirrer. 3.3 g. of 2-chloro-6β-fluoro-17α,21-dihydroxy-9β,11β-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7a, R₃ =H) were added under stirring during 15 min. After 1.5 hr. the reaction mixture was pecipitated in water and ammonia. The solid was collected by filtration, washed with water and dried to a constant weight, giving about 3 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8a, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =H).

Crystallization from benzene gave 2.5 g. of pure product.

M.P. 285°-6° C. (decomposition).

[α]_(D) -24° (C 0.5 in chloroform).

λmax (methanol) 244-5 mμ (ε13700).

IR(KBr) 3520, 1755, 1730, 1705, 1680, 1645, 1610, 1230 cm⁻¹.

NMR (dimethyl-d₆ sulfoxide-TMS) Hz at 60 mHz 452 (S, 1, C₁ -H) 390,386 (d, 1, C₄ -H) 346,296 (doublet of triplets, 1,C₆ -H) 337,332 (d, 1, C₁₁ -OH) 286 (S, 2, --CH₂ OAc) 264-240 (m, 1, C₁₁ -H) 126 (S, 3, OAc) 120 (S, 3, OAc) 98,94 (d, 3, C₁₀ -CH₃ split by 6βF) 55 (S, 3, C₁₃ -CH₃).

Analysis: Calcd. for C₂₅ H₂₉ ClF₂ O₇ (percent) C 58,31;H 5,68;Cl 6,88; F 7,38. Found (percent) C 58,50; H 5,72; Cl 6,83; F 7,43.

EXAMPLE XVII

Using the general procedure of Example XVI the 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-9β,11β-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7b, R₃ =αCH₃) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8b, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =αCH₃) characterized by:

IR(KBr) 3525, 1755, 1730, 1705, 1680, 1640, 1610, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ ClF₂ O₇ (percent) C 59,04; H 5,91; Cl 6,70; F 7.18. Found (percent) C 59,11; H 5,92; Cl 6,75; F 7,12.

EXAMPLE XVIII

Using the general procedure of Example XVI the 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-9β,11.beta.-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7c, R₃ =βCH₃) was converted into 2-chloro-6β,9α-difluoro-11β;17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (Sc, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =αCH₃) characterized by:

IR(KBr) 3520, 1755, 1740, 1710, 1680, 1640, 1610, 1235 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ ClF₂ O₇ (percent) C 59,04; H 5,91; Cl 6,70; F 7,18. Found (percent) C 58,93; H 5,80; Cl 6,65; F 7,14.

EXAMPLE XIX

50 ml. of hydrochloric acid were added at 0° C. over a period of 40 min. to a suspension of 5 g. of 2-chloro-6β-fluoro-17α,21-dihydroxy-9β,11β-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7a, R₃ =H) in 30 ml. of acetone. The mixture was held at 0° C. with stirring for about 15 min. and then the precipitated 2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8d, X=OH, Y=Cl, R₃ =H, R₁ =R₂ =OCOCH₃) was recovered by filtration, washed repeatedly with water and dried (4.9 g.).

IR(KBr) 3440 (broad), 1755, 1740, 1705, 1675, 1640, 1600, 1230 cm⁻¹.

Analysis: Calcd. for C₂₅ H₂₉ Cl₉ FO₇ (percent) C 56,51; H 5,50; Cl 13,34; F 3,57. Found (percent) C 56,55; H 4,57; Cl 13,28; F 3,53.

EXAMPLE XX

Using the general procedure of Example XIX the 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-9β,11β-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7b, R₃ =αCH₃) was converted into 2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8e, X=OH, Y=Cl, R₃ =αCH₃, R₁ =R₂ =OCOCH₃)

IR(KBr) 3445 (broad), 1755, 1740, 1705, 1675, 1640, 1600, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ Cl₂ FO₇ (percent) C 57,25; H 5,73; Cl 13,00; F 3,48. Found (percent) C 57,34; H 5,71; Cl 12,95; F 3,51.

EXAMPLE XXI

Using the general procedure of Example XIX the 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-9β,11.beta.-oxido-pregna-1,4-diene-3,20-dione-17,21-diacetate (7c, R₃ =βCH₃) was converted into 2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8f, X=OH, Y=Cl, R₁ =R₂ =OCOCH₃, R₃ =βCH₃) characterized by:

IR(KBr) 3440 (broad), 1750, 1738, 1705, 1675, 1645, 1605, 1230 cm⁻¹.

Analysis Calcd. for C₂₆ H₃₁ Cl₂ FO₇ (percent) C 57,25; H 5,73; Cl 13,00; F 3,48; Found (percent) C 57,45 H 5,75; Cl 13,12; F 3,53.

EXAMPLE XXII

To a solution of 6.8 g. of 2-chloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5a, R₃ =H) and 2.8 g. of lithium chloride in 120 ml. of glacial acetic acid were added at 20° C. under stirring 3.4 g. of N-chlorosuccinimide. The mixture was kept at 20° C. and stirred while dropwise adding 7 ml. of a 12% hydrochloric acid tetrahydrofurane solution over a period of about 10 min. After 3.5 hr. the reaction mixture was poured into cold water, the solid was collected by filtration, washed with water and dried, giving 6 g. of 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8g, X=Y=Cl, R₁ =R₂ =OCOCH₃, R₃ =H) crystallized by methanol.

M.P. 248°-9° C. (decomposition).

[α]_(D) ²⁰ -3° (C 1.0 in chloroform).

λmax (methanol) 243 mμ (ε13000).

IR(KBr) 1755, 1745, 1680, 1650, 1612, 1235 cm⁻¹.

Analysis: Calcd. for C₂₅ H₂₈ Cl₃ FO₆ (percent) C 54,61; H 5,13; Cl 19,34; F 3.46. Found (percent) C 54,75; H 5,09; Cl 19,25; F 3,42.

EXAMPLE XXIII

Using the general procedure of Example XXII the 2-chloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5b, R₃ =αCH₃) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8h, R₃ =αCH₃, R₁ =R₂ =OCOCH₃, X=Y=Cl) characterized by:

IR(KBr) 1760, 1740, 1678, 1645, 1610, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₀ Cl₃ FO₆ (percent) C 55,38; H 5,36; Cl 18,86; F 3.37. Found (percent) C 55,32; H 5,34; Cl 18,80; F 3,35.

EXAMPLE XXIV

Using the general procedure of Example XXII the 2-chloro-6β-fluoro-17α,21-dihydroxy-16β-methyl-pregna-1,4,9(11)-triene-3,20-dione-17,21-diacetate (5c, R₃ =βCH₃) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8i, R₃ =βCH₃, R₁ =R₂ =OCOCH₃, X=Y=Cl) characterized by:

IR(KBr) 1755, 1740, 1680, 1640, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₀ Cl₃ FO₆ (percent) C 55,38; H 5,36; Cl 18,86; F 3,37. Found (percent) C 55,59; H 5,33; Cl 18,82; F 3,35.

EXAMPLE XXV

A suspension of 2 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8a, X=OH, Y=F, R₃ =H, R₁ =R₂ =OCOCH₃) in 40 ml. of 1% potassium hydroxide methanolic solution was stirred under nitrogen at 0° C. for 3 hrs.

Addition of cold water, elimination of methanol in vacuo, acidification with acetic acid, filtration and crystallization from dichloroethane-petroleum ether gave 1 g. of 2-choro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, X=OH, Y=F, R₁ =R₂ =OH, R₃ =H).

M.P. 219°-21° C. (decomposition).

[α]_(D) ²⁰ +5° (C 1.0 in chloroform).

λmax (methanol) 245 mμ (ε11800).

IR(KBr) 3440, 1715, 1670, 1640, 1600 cm⁻¹.

Analysis: Calcd. for C₂₁ H₂₅ ClF₂ O₅ (percent) C 58,54; H 5,85; Cl 8,23; F 8,82. Found (percent) C 58,75; H 5,91; Cl 8,25; F 8,91.

EXAMPLE XXVI

Using the general procedure of Example XXV the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8b, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =αCH₃) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione (8k, X=OH, Y=F, R₁ =R₂ =OH, R₃ =αCH₃).

IR(KBr) 3440, 1712, 1670, 1640, 1600 cm⁻¹.

Analysis: Caled. for C₂₂ H₂₇ ClF₂ O₅ (percent) C 59,39; H 6,12; Cl 7,97; F 8.54; Found (percent) C 59,46; H 6,21; Cl 8,06; F 8,61.

EXAMPLE XXVII

Using the general procedure of Example XXV the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-dione-3,20-dione-17,21-diacetate (8c, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =βCH₃) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l, X=OH, Y=F, R₁ =R₂ =OH, R₃ =βCH₃).

IR(KBr) 3430, 1715, 1675, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₂ H₂₇ ClF₂ O₅ (percent) C 59,39; H 6,12; Cl 7,97; F 8,54. Found (percent) C 59,43; H 6,12; Cl 7,98; F 8,60.

EXAMPLE XXVIII

Using the general procedure of Example XXV the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8g, R₁ =R₂ =OCOCH₃, R₃ =H, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione (8m, R₁ =R₂ =OH, R₃ =H, X=Y=Cl).

IR(KBr) 3450 (broad), 1710, 1675, 1610 cm⁻¹.

Analysis: Calcd. for C₂₁ H₂₄ Cl₃ FO₄ (percent) C 54,15; H 5,19; Cl 22,83; F 4,08. Found (percent) C 54,25; H 5,21; Cl 22,91; F 4,12.

EXAMPLE XXIX

Using the general procedure of Example XXV the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-diacetate (8h, R₁ =R₂ =OCOCH₃, R₃ =αCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16α-methyl-pregna-1,4-diene-3,20-dione (8n, R₁ =R₂ =OH, X=Y=Cl, R₃ =αCH₃).

IR(KBr) 3460 (broad), 1710, 1675, 1610 cm⁻¹.

Analysis: Calcd. for C₂₂ H₂₆ Cl₃ FO₄ (percent) C 55,07; H 5,46; Cl 22,17; F 3.96. Found (percent) C 55,13; H 5,42; Cl 22,18; F 3,95.

EXAMPLE XXX

Using the general procedure of Example XXV the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pergna-1,4-diene-3,20-dione-17,21-diacetate (8i, R₁ =R₂ =OCOCH₃, R₃ =βCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8o, R₁ =R₂ =OH, R₃ =βCH₃, X=Y=Cl).

IR(KBr) 3450 (broad), 1712, 1672, 1610 cm⁻¹.

Analysis: Calcd. for C₂₂ H₂₆ Cl₃ FO₄ (percent) C 55,07; H 5,46; Cl 22,17; F 3,96. Found (percent) C 55,18; H 5,52; Cl 22,23; F 3,98.

EXAMPLE XXXI

2.9 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, R₁ =R₂ =OH, R₃ =H, X=OH, Y=F) were dissolved in 29 ml. of pyridine containing 15 ml. of acetic anhydride and kept at room temperature for 12 hrs. Addition of ice water afforded a product which was extracted with chloroform. The chloroform solution was washed with water, HCl2N, 5% sodium bicarbonate solution and water.

After drying (Na₂ SO₄) and removal of the solvent in vacuo the residue was crystallized from acetone-hexane to give 1.7 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-acetate (8p, R₁ =OCOCH₃, R₂ =OH, X=OH, Y=F, R₃ =H).

M.P. 225°-27° C.

[α]_(D) +21° (C 1.0 in chloroform).

IR(CHCl₃) 3700, 3620, 1750, 1735, 1680, 1650, 1610.

Analysis: Calcd. for C₂₃ H₂₇ ClF₂ O₆ (percent) C 58,42; H 5,75; Cl 7,50; F 8,03. Found (percent) C 58,60; H 5,80; Cl 7,50; F 8,02.

EXAMPLE XXXII

Using the general procedure of Example XXXI the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8k, R₁ =R₂ =CH, R₃ =αCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8q, R₁ =OCOCH₃, R₂ =OH, R₃ =αCH₃, X=OH, Y=F).

IR(CHCl₃) 3700, 3620, 1750, 1730, 1680, 1645, 1605.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₆ (percent) C 59,20; H 6,00; Cl 7,28; F 7,80. Found (percent) C 59,32; H 6,02; Cl 7,35; F 7,83.

EXAMPLE XXXIII

Using the general procedure of Example XXXI the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l, R₁ =R₂ =OH, R₃ =βCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8r, R₁ =OCOCH₃, R₂ =OH, X=OH, Y=F, R₃ =βCH₃).

IR(CHCl₃) 3705, 3620, 1745, 1730, 1680, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₆ (percent) C 59,20; H 6,00; Cl 7,28; F 7,80. Found (percent) C 59,40; H 6,05; Cl 7,35; F 7,82.

EXAMPLE XXXIV

Using the general procedure of Example XXXI the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione (8m, R₁ =R₂ =OH, R₃ =H, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-21-acetate (8s, R₁ =OCOCH₃, R₂ =OH, R₃ =H, X=Y=Cl).

IR(CHCl₃) 3600 (broad), 1740, 1730, 1680, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₃ H₂₆ Cl₃ FO₅ (percent) C 54,40; H 5,16; Cl 20,94; F 3,74. Found (percent) C 54,56; H 5,16; Cl 20,90; F 3,80.

EXAMPLE XXXV

Using the general procedure of Example XXXI the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8n, R₁ =R₂ =OR, R₃ =αCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8t, R₁ =OCOCH₃, R₂ =OH, R₃ =αCH₃, X=Y=Cl).

IR(CHCl₃) 3600 (broad), 1742, 1730, 1680, 1640, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₈ Cl₃ FO₅ (percent) C 55,24; H 5,41; Cl 20,38; F 3,64. Found (percent) C 55,32; H 5,43; Cl 20,42; F 3,68.

EXAMPLE XXXVI

Using the general procedure of Example XXXI the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8o, R₁ =R₂ =OH, R₃ =βCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-acetate (8u, R₁ =OCOCH₃, R₂ =OH, R₃ =βCH₃, X=Y=Cl).

IR(CHCl₃) 3610 (broad), 1740, 1728, 1675, 1645, 1610, 1235 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₈ Cl₃ FO₅ (percent) C 55,24; H 5,41; Cl 20,38; F 3,64. Found (percent) C 55,20; H 5,53; Cl 20,47; F 3,62.

EXAMPLE XXXVII

Using the general procedure of Example XXXI the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, R₁ =R₂ =OH, R₃ =H, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8v, R₁ =OCOCH₂ CH₂ COOH, R₂ =OH, R₃ =H, X=OH, Y=F) which was crystallized from water.

M.P. 149°-152° C.

[α]_(D) ²⁰ +26° (C 1.0 in dioxane).

λmax (methanol) 244-5 mμ (ε12600).

IR(KBr) 3500 (broad), 1730 (broad), 1670, 1640, 1610 cm⁻¹.

Analysis: Calcd. for C₂₅ H₂₉ ClF₂ O₈ (percent) C 56,55; H 5,51; Cl 6,68; F 7,16. Found (percent) C 56,81; H 5,55; Cl 6,72; F 7,12.

EXAMPLE XXXVIII

Using the general procedure of Example XXXI the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8k, R₁ =R₂ =OH, R₃ =αCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8w, R₁ =OCOCH₂ CH₂ COOH, R₂ =OH, R₃ =αCH₃, X=OH, Y=F) which was crystallized from water.

IR(KBr) 3500 (broad), 1725, 1675, 1640, 1610 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ ClF₂ O₈ (percent) C 57,30; H 5,73; Cl 6,51; F 6,97. Found (percent) C 57,45; H 5,72; Cl 6,49; F 6,91.

EXAMPLE XXXIX

Using the general procedure of Example XXXI the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l, R₁ =R₂ =OH, R₃ =βCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8z, R₁ =OCOCH₂ CH₂ COOH, R₂ =OH, R₃ =βCH₃, X=OH, Y=F) which was crystallized from water.

IR(KBr) 3500 (broad), 1730, 1680, 1640, 1610 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ ClF₂ O₈ (percent) C 57,30; H 5,73; Cl 6,51; F 6,97. Found (percent) C 57,45; H 5,81; Cl 6,57; F 7,02.

EXAMPLE XL

0.1 N NaOH solution was slowly added to a stirred solution of 1.9 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate in 50 ml. of acetone until the pH rose to 7.4. During the addition of NaOH solution, 100 ml. of water were also added. The solution was concentrated at 25° C. under vacuum to remove the acetone. The resulting aqueous solution was filtered and freeze-dried to give 1.9 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8 aa, R₁ =OCOCH₂ CH₂ COONa, R₂ =OH, R₃ =H, X=OH, Y=F).

[α]_(D) ²⁰ +33° (C 0.5 in water).

λmax (methanol) 245 mμ (ε11500).

IR(KBr) 3470 (broad), 1725, 1675, 1645, 1580 (broad).

EXAMPLE XLI

Using the general procedure of Example XL the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8w, R₁ =OCOCH₂ CH₂ COOH, R₂ =OH, R₃ =αCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8 ab, R₁ =OCOCH₂ CH₂ COONa, R₂ =OH, R₃ =αCH₃, X=OH, Y=F).

IR(KBr) 3480 (broad), 1670, 1640, 1580 (broad).

EXAMPLE XLII

Using the general procedure of Example XL the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate (8z, R₁ =OCOCH₂ CH₂ COOH, R₂ =OH, R₃ =βCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt (8 ac, R₁ =OCOCH₂ CH₂ COONa, R₂ =OH, R₃ =βCH₃, X=OH, Y=F).

IR(KBr) 3490 (broad), 1675, 1645, 1580 (broad).

EXAMPLE XLIII

A mixture of 5 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, R₁ =R₂ =OH, R₃ =H, X=OH, Y=F), 5 ml. of methylorthovalerate and 0.020 g. of p-toluenesulfonic acid in 15 ml. of dimethylformamide was maintained for 4 hrs. under nitrogen at 115° C. Then the mixture was neutralized by pyridine and concentrated under vacuum to dryness. Purification by column chromatography on FLORISIL (Registered Trade Mark) (ratio 1:150) with benzene-chloroform (1:1) as eluant, gave 4 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-(1'-methoxy)-n-pentylidenedioxy which, without further purification, was suspended in 25 ml. of methanol and 3 ml. of 1 N hydrochloric acid aqueous solution, heated on water bath at 40°-50° C.

After complete solubilization of the product, the mixture was concentrated under vacuum. The insoluble product was filtered off, washed with water and then dried.

The 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-valerate (8 ad, R₁ =OH, R₂ =OCO(CH₂)₃ CH₃, R₃ =H, X=OH, Y=F) thus obtained was crystallized from acetone-n-hexane and characterized by:

IR(KBr) 3500 (broad), 1730, 1710, 1675, 1645, 1600 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₃ ClF₂ O₆ (percent) C 60,64; H 6,46; Cl 6,88; F 7,38. Found (percent) C 60,70; H 6,45; Cl 6,88; F 7,35.

EXAMPLE XLIV

Using the general procedure of Example XLIII the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, R₁ =R₂ =OH, R₃ =H, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-acetate (8 ae, R₁ =OH,R₂ =OCOCH₃, R₃ =H, X=OH, Y=F) by reaction with ethylorthoacetate followed by hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3490 (broad), 1730, 1710, 1670, 1645, 1600 cm⁻¹.

Analysis: Calcd. for C₂₃ H₂₇ ClF₂ O₆ (percent) C 58,42; H 5,75; Cl 7, 0; F 8,03. Found (percent) C 58,52; H 5,80; Cl 7,50; F 8,00.

EXAMPLE XLV

Using the general procedure of Example XLIII the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8k, R₁ =R₂ =OH, R₃ =αCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8 af, R₁ =OH, R₂ =OCOCH₃, X=OH, Y=F, R₃ =αCH₃) by reaction with ethylorthoacetate followed by hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3500 (broad), 1735 (broad), 1675, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₆ (percent) C 59,20; H 6,00; Cl 7,28; F 7,80. Found (percent) C 59,29; H 6,02; Cl 7,31; F 7,78.

EXAMPLE XLVI

Using the general procedure of Example XLIII the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l, R₁ =R₂ =OH, R₃ =βCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8 ag, R₁ =OH, R₂ =OCOCH₃, R₃ =βCH₃, X=OH, Y=F) by reaction with ethylorthoacetate followed by hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3500 (broad), 1730 (broad), 1672, 1645, 1600 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₆ (percent) C 59,20; H 6,00; Cl 7,28; F 7,80. Found (percent) C 59,15; H 5,98; Cl 7,35; F 7,78.

EXAMPLE XLVII

Using the general procedure of Example XLIII the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione (8m, R₁ =R₂ =OH, R₃ =H, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-pregna-1,4-diene-3,20-dione-17-acetate (8 ah, R₁ =OH, R₂ =OCOCH₃, R₃ =H, X=Y=Cl) by reaction with ethylorthoacetate followed by acid hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3500 (broad), 1730, 1715, 1672, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₃ H₂₆ Cl₃ FO₅ (percent) C 54,40; H 5,16; Cl 20,94; F 3,74. Found (percent) C 54,60; H 5,12; Cl 20,92; F 3,76.

EXAMPLE XLVIII

Using the general procedure of Example XLIII the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8n, R₁ =R₂ =OH, R₃ =αCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8 ai, R₁ =OH, R₂ =OCOCH₃, R₃ =αCH₃, X=Y=Cl) by reaction with ethylorthoacetate followed by acid hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3500 (broad), 1728, 1715, 1670, 1645, 1600, 1230 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₈ Cl₃ FO₅ (percent) C 55,24; H 5,41; Cl 20,38; F 3,64. Found (percent) C 55,32; H 5,50; Cl 20,36; F 3,64.

EXAMPLE XLIX

Using the general procedure of Example XLIII the 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8o, R₁ =R₂ =OH, R₃ =βCH₃, X=Y=Cl) was converted into 2,9α,11β-trichloro-6β-fluoro-17α,21-dihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17-acetate (8 aj, R₁ =OH, R₂ =OCOCH₃, R₃ =βCH₃, X=Y=Cl) by reaction with ethylorthoacetate followed by acid hydrolysis of the resulting 17,21-orthoacetate.

IR(KBr) 3500 (broad), 1730, 1712, 1673, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₈ Cl₃ FO₅ (percent) C 55,24; H 5,41; Cl 20;38; F 3,64. Found (percent) C 55,20; H 5,40; Cl 20,35; F 3,62.

EXAMPLE L

A solution of 6 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione (8j, X=OH, Y=F, R₁ =R₂ =OH, R₃ =H) in 12 ml. of dimethylformamide and 40 ml. of 2,2-dimethoxypropane with 0.030 g. of p-toluenesulfonic acid was heated for 5 hrs. at 115° C.

The reaction mixture was cooled, poured in 10% sodium bicarbonate aqueous solution and chloroform. The chloroform solution was then washed with water, dried and evaporated to a residue which by crystallization from acetone-hexane gave 5 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-acetonide (8 ak).

IR(KBr) 3450 (broad), 1720, 1672, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₅ (percent) C 61,21; H 6,21; Cl 7,53; F 8,07. Found (percent) C 61,27; H 6,22; Cl 7,55; F 8,09.

EXAMPLE LI

Using the general procedure of Example L the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione (8k, X=OH, Y=F, R₁ =R₂ =OH, R₃ =αCH₃) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.alpha.-methyl-pregna-1,4-diene-3,20-dione-17,21-acetonide (8 al) characterized by:

IR(KBr) 3480 (broad), 1725, 1670, 1645, 1610 cm⁻¹.

Analysis: Calcd. for C₂₅ H₃₁ ClF₂ O₅ (percent) C 61,92; H 6,44; Cl 7,31; F 7,83. Found (percent) C 62,07; H 6,39; Cl 7,35; F 7,85.

EXAMPLE LII

Using the general procedure of Example L the 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione (8l, R₁ =R₂ =OH, R₃ =βCH₃, X=OH, Y=F) was converted into 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-16.beta.-methyl-pregna-1,4-diene-3,20-dione-17,21-acetonide (8 am), characterized by:

IR(KBr) 3500 (broad), 1730, 1675, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₅ H₃₁ ClF₂ O₅ (percent) C 61,92; H 6,44; Cl 7,31; F 7,83. Found (percent) C 61,98; H 6,44; Cl 7,36; F 7,85.

EXAMPLE LIII

A mixture of 10 g. of 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate (8a, X=OH, Y=F, R₁ =R₂ =OCOCH₃, R₃ =H), in 100 ml. of dimethylformamide and 50 g. of anhydrous potassium acetate was refluxed at 120° C. under nitrogen for 0.5 hr. The reaction mixture was then cooled and poured into cold water.

The precipitate was filtered off, washed with water, dried. Crystallization of the residue from acetone-hexane gave 7.5 g. of 2-chloro-6β,9α-difluoro-11β,21-dihydroxy-pregna-1,4,16-triene-3,20-dione-21-acetate (9a, X=OH, Y=F, R₁ =OCOCH₃) characterized by:

IR(KBr) 3520, 1730, 1680, 1645, 1605, 1590, 1220 cm⁻¹.

Analysis: Calcd. for C₂₃ H₂₅ ClF₂ O₅ (percent) C 60,73; H 5,54; Cl 7,79; F 8,35. Found (percent) C 60,83; H 5,60; Cl 7,82; F 8,37.

EXAMPLE LIV

A solution of potassium permanganate (5 g.) in acetone (100 ml.) and water (30 ml.) was added, in one portion, at -50° C. to a solution of 7 g. of 2-chloro-6β,9α-difluoro-11β,21-dihydroxy-pregna-1,4,16-triene-3,20-dione-21-acetate (9a, X=OH, Y=F, R₁ =OCOCH₃) in acetone (200 ml.) and formic acid (2.5 ml.).

The reaction mixture was stirred for 5 minutes at -5° C. and then 50 ml. of 10% Na₂ SO₃ aqueous solution were added. The mixture was filtered through Celite (Registered Trade Mark) and the filtrate concentrated in vacuo and poured into cold water.

The solid filtered after crystallization from acetone-hexane yielded 6.5 g. of 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10a, X=OH, Y=F, R₁ =OCOCH₃) characterized by

IR(KBr) 3450 (broad), 1745, 1730, 1675, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₃ H₂₇ ClF₂ O₇ (percent) C 56,50; H 5,57; Cl 7,25; F 7,77. Found (percent) C 56,56; H 5,61; Cl 7,27; F 7,80.

EXAMPLE LV

Using the general procedure of Example XXV the 2-chloro-6β,9α-difluoro -11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10a, X=OH, Y=F, R₁ =OCOCH₃) was converted into 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione (10b, X=OH, Y=F, R₁ =OH) characterized by:

IR(KBr) 3480 (broad), 1715, 1670, 1645, 1605 cm⁻¹.

Analysis: Calcd. for C₂₁ H₂₅ ClF₂ O₆ (percent) C 56,44; H 5,64; Cl 7,93; F 8,50. Found (percent) C 56,31; H 5,62; Cl 7.98; F 8,45.

EXAMPLE LVI

2.5 ml. of 70% perchloric acid were added under stirring at 15° C. to a suspension of 10 g. of 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10a, X=OH, Y=F, R₁ =OCOCH₃) in 400 ml. of acetone. The solution was stirred at 15° C. for 50 minutes and 5 g. of sodium bicarbonate were added. The mixture was stirred for 10 minutes and then filtered.

The acetone solution was evaporated to dryness in vacuo at 60° C. The solid residue was crystallized from ethylacetate-light petroleum giving 6 g. of pure 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy -pregna-1,4-diene-3,20-dione-21-acetate-16,17-acetonide (11a, X=OH, Y=F, R₁ =OCOCH₃, R₄ =R₅ CH₃) characterized by:

IR(KBr) 3560, 3480, 3420, 1755, 1730, 1670, 1645, 1605, 1230 cm⁻¹.

Analysis: Calcd. for C₂₆ H₃₁ ClF₂ O₇ (percent) C 59,04; H 5,91; Cl 6,70 F 7,18. Found (percent) C 59,15; H 5,88; Cl 6,72; F 7,15.

EXAMPLE LVII

Using the general procedure of Example LVI the 2-chloro-6β,9α-difluoro -11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-diione (10b, X=OH, Y=F, R₁ =OH) was converted into 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-16,17-acetonide (11b, X=OH, Y=F, R₁ =OH, R₄ =R₅ =CH₃).

IR(KBr) 3500, 3280, 1725, 1670, 1645, 1600 cm⁻¹.

Analysis: Calcd. for C₂₄ H₂₉ ClF₂ O₆ (percent) C 59,20; H 6,00; Cl 7,28; F 7,80. Found (percent) C 59,32; H 6,09; Cl 7,31; F 7,78.

EXAMPLE LVIII

5 ml. of acetic anhydride were dropwise added to a mixture of 50 ml. of pyridine and 10 g. of 2-chloro-6β,9α-difluoro-11β,16α,17α,21-tetrahydroxy-pregna-1,4-diene-3,20-dione-21-acetate (10a, X=OH, Y=F, R₁ =OCOCH₃). The mixture was kept at room temperature for 1.5 hr. and then poured under vigorous stirring into 1500 ml. of cold water.

After about 0.5 hr. the solid was collected by filtration, washed thoroughly with cold water, dried to a constant weight, giving about 9 g. of 2-chloro-6β,9α-difluoro-11β, 16α,17α21-tetrahydroxy-pregna-1,4-diene-3,20-dione-16,21-diacetate (12a, X=OH, Y=F, R₁ =R₃ =OCOCH₃).

IR(KBr) 3570, 3500 (broad), 1760, 1740 (broad), 1675, 1645, 1605, 1225 cm⁻¹.

Analysis: Calcd. for C₂₅ H₂₉ ClF₂ O₈ (percent) C 56,55; H 5,51; Cl 6,68; F 7,16. Found (percent) C 56,61; H 5,51; Cl 6,72; F 7,16. 

We claim:
 1. A compound having the formula: ##STR3## wherein X is Br, Cl or OQ, Y is Br, Cl, F or H, R₁ is OQ, R₂ is OQ and R₃ is H, or αOQ, and Q, which may be the same or different, is H, or acyl radicals, or OQ in the 16,17 or in the 17,21 positions may together form a cyclic ketal, cyclic acetal or cyclic alkyl orthoester, and pharmaceutically acceptable salts and esters of those compounds wherein at least one radical Q is a polycarboxylic or an inorganic acid radical.
 2. The compound according to claim 1 in which X represents OH.
 3. The compound according to claim 1 in which Y represents fluorine.
 4. The compound according to claim 1 in which OQ in the 21 position forms an inorganic ester with their salts.
 5. A pharmaceutical composition comprising an active compound according to claim 1 together with a pharmaceutically acceptable carrier.
 6. A method of combatting inflammation in a patient comprising applying a compound according to claim 1 to the patient topically or or systemically in a non-toxic pharmaceutically effective amount.
 7. A compound having the formula: ##STR4## wherein X is Br, Cl or OQ, Y is Br, Cl, F or H, R₁ is OQ, R₂ is OQ and R₃ is αOQ, and Q in the 16,17 and 21 positions represents H.
 8. A compound having the formula: ##STR5## wherein X is Br, Cl or OQ, Y is Br, Cl, F or H, R₁ is OQ in the 21 position and forms an alkyl orthoester, R₂ is OQ and R₃ is H, αOQ, αCH₃ or βCH₃, and Q, which may be the same or different, is H, or acyl radicals, or OQ in the 16,17 or in the 17,21 positions may together form a cyclic alkyl orthoester, and pharmaceutically acceptable salts and esters of those compounds wherein at least one radical Q is a polycarboxylic or an inorganic acid radical.
 9. The compound according to claim 1 wherein X is Br or Cl and Y is Br, Cl or F.
 10. The compound according to claim 1 wherein X is OH and Y is Br, Cl or F.
 11. The compound according to claim 1 wherein Y is Br.
 12. The compound according to claim 7 wherein X is OH.
 13. The compound according to claim 7 wherein Y is F.
 14. The compound according to claim 7 wherein X is Br or Cl and Y is Br, Cl or F.
 15. The compound according to claim 7 wherein X is OH and Y is Br, Cl or F.
 16. The compound according to claim 7 wherein Y is Br.
 17. A pharmaceutical composition comprising an active compound according to claim 7 together with a pharmaceutically acceptable carrier.
 18. A method of combatting inflammation in a patient comprising applying a compound according to claim 7 to the patient topically or systemically in a non-toxic pharmaceutically effective amount.
 19. The compound according to claim 8 wherein X is OH.
 20. The compound according to claim 8 wherein Y is F.
 21. The compound according to claim 8 wherein X is Br or Cl and Y is Br, Cl or F.
 22. The compound according to claim 8 wherein X is OH and Y is Br, Cl or F.
 23. The compound according to claim 8 wherein Y is Br.
 24. A pharmaceutical composition comprising an active compound according to claim 8 together with a pharmaceutically acceptable carrier.
 25. A method of combatting inflammation in a patient comprising applying a compound according to claim 8 to the patient topically or systemically in a non-toxic pharmaceutically effective amount.
 26. The compound of claim 1 which is a 9α-bromo-2-chloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate.
 27. The compound of claim 1 which is a 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate.
 28. The compound of claim 1 which is a 2,9α-dichloro-6β-fluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-diacetate.
 29. The compound of claim 1 which is a 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione.
 30. The compound of claim 1 which is a 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-acetate.
 31. The compound of claim 1 which is 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate.
 32. The compound of claim 1 which is 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-21-hemisuccinate sodium salt.
 33. The compound of claim 1 which is 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-valerate.
 34. The compound of claim 1 which is 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17-acetate.
 35. The compound of claim 1 which is 2-chloro-6β,9α-difluoro-11β,17α,21-trihydroxy-pregna-1,4-diene-3,20-dione-17,21-acetonide. 